Royal College of Surgeons in Ireland, 123 St Stephen's Green, Dublin, D02 YN77, Republic of Ireland.
Moorfields Eye Hospital NHS Foundation Trust, 162 City Road, London, EC1V 2PD, United Kingdom.
Eye (Lond). 2023 Sep;37(13):2817-2825. doi: 10.1038/s41433-023-02425-y. Epub 2023 Feb 10.
Birdshot Retinochoroiditis (BSRC) is a rare, chronic posterior uveitis that is strongly associated with HLA-A*29.2 positivity. To date, no robust incidence studies of BSRC have been undertaken. We present the first epidemiological study of BSRC in a high-prevalence region.
In collaboration with the British Ophthalmological Surveillance Unit, all new cases of BSRC between May 2017 and June 2019 were prospectively collected. Presenting demographics, symptoms, signs and treatment modalities were collected. A follow-up questionnaire twelve months later was also sent.
Thirty-seven confirmed cases meeting the reporting criteria were identified. Twenty-three cases had both baseline and follow-up data. The total population incidence of BSRC was 0.035 cases per 100,000 person-years [95% CI 0.025-0.048 cases per 100 000 people]. 97.3% were HLA-A*29 positive. The median age was 46 years, with females making up 78% of patients. There were no significant differences in the latitudinal incidence of BSRC. At presentation, floaters were the most common symptom. Optic disc swelling was the most common sign. Mean presenting visual acuity was independent of symptom duration. Combined systemic corticosteroids and immunomodulatory therapy were the most common treatments at baseline and follow-up. Intravitreal steroids were equally popular at follow-up.
This study provides the first nationwide estimate of the incidence of BSRC in a high-prevalence region. Cases were more common in females, with a broad range of presentation ages. No significant latitudinal effect of incidence was identified. Systemic therapy with steroids and IMT remain the most common treatments.
鸟枪弹样视网膜脉络膜炎(BSRC)是一种罕见的慢性后葡萄膜炎,与 HLA-A*29.2 阳性密切相关。迄今为止,尚未对 BSRC 进行过大规模的发病率研究。我们首次在高发地区开展了 BSRC 的流行病学研究。
与英国眼科监测单位合作,前瞻性收集了 2017 年 5 月至 2019 年 6 月期间所有新发的 BSRC 病例。收集了患者的首发症状、体征和治疗方法等数据。12 个月后还发送了一份随访问卷。
共确定了 37 例符合报告标准的确诊病例。其中 23 例患者有基线和随访数据。BSRC 的总人群发病率为 0.035 例/10 万人年[95%可信区间 0.025-0.048 例/10 万人]。97.3%的患者 HLA-A*29 阳性。中位年龄为 46 岁,女性占患者的 78%。BSRC 的发病率在纬度上没有显著差异。在首发时,最常见的症状是漂浮物。视盘肿胀是最常见的体征。在就诊时的视力与症状持续时间无关。基线和随访时最常见的治疗方法是联合全身皮质类固醇和免疫调节剂治疗。在随访时,玻璃体内注射皮质类固醇同样受欢迎。
本研究首次提供了高发地区 BSRC 发病率的全国性估计。女性病例较多,发病年龄广泛。未发现发病率的显著纬度效应。以皮质类固醇和 IMT 为主的全身治疗仍然是最常见的治疗方法。